samedan logo
 
 
 
spacer
home > pmps > autumn 2020 > accelerating nanotherapeutics
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Accelerating Nanotherapeutics

A tide has slowly been turning in the field of medicine; we are beginning to move beyond traditional small molecule drugs towards complex medicines, which are reliant on the use of advanced drug delivery systems. These medicines could, potentially, have enormous, life-changing impacts on human society and provide more focused, tailored treatments compared with historical therapies. Complex medicines – viral vectors, antibody-drug conjugates, nanomedicines, and gene therapies to name a few – are beginning to address more complex diseases. From gene editing approaches to targeted cancer treatments, these therapies offer promising treatment options for diseases with unmet clinical needs, moving beyond a one-size-fits-all approach.

Many established medical treatments, for example, traditional chemotherapy, are non-selective. This means there is no ability to target specific cells, and healthy cells can be impacted, potentially leading to negative side effects for the patient. As a result, there is a growing demand for treatments that can better target specific cells using complex approaches, such as nanotherapeutics – engineered nanomaterials designed to deliver medical substances with high specificity to a targeted site.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Caroline Kelly, Technology and Innovation Officer at CPI, earned her degree and PhD in Chemistry from University of Cambridge, UK, and has held a range of technical roles, working across different sectors within the formulation industry. Her early career included time at large corporations, such as Esso, ICI, and Croda, and more recent roles in chemical distribution and with SMEs. Caroline joined CPI in 2016 to manage a programme of strategic projects within CPI’s National Formulation Centre, working with industry and academia to build new capability to support companies active in formulation within the UK.
spacer
Dr Caroline Kelly
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck to Provide BioReliance® End-to-End Solutions to Phanes Therapeutics

• Collaboration to accelerate development and manufacturing of Bispecific Antibody • Merck plans to offer Phanes a full suite of products and services under its BioReliance® offering
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement